Data & Technology in Clinical Trials 2015
Teaming up with Eli Lilly and DrugDev Advisory Board, eyeforpharma conducted a 'State of the Industry' survey to investigate how pharma is currently leveraging data and technology and how this will change over the next 2 years.
Highlights include:
- Adopt a risk based approach for a cheaper way to clean your data, ensure optimum data quality and patient safety
- Integrate real world and real time data for faster data generation, to quickly demonstrate value to patients and find urgent answers to unmet needs
- Overcome rising R&D costs by utilising big data to identify patient sub groups, integrate patients into research stages to better identify new biomarkers and provide more personalised treatments
- See how mobile and wearable devices encourage patient participation by virtualising parts of trials, reduce patient burden and enhance data quality
Please subscribe to view the analysis report